TACSTD2 and prostate carcinoma: Of therapeutic relevance, we also demonstrate that (vi) the GSE1 and TACSTD2 interaction, or expression profiles, reflect abiraterone/enzalutamide drug resistance, androgen sensitivity, and castration resistance in patients with prostate cancer and posit that (vi) targeting GSE1 signaling suppresses metastatic and cancer stemness phenotypes and enhances sensitivity to abiraterone or enzalutamide in metastatic castration-resistant PCa in vitro and in vivo.